VeraBank N.A. Sells 1,675 Shares of Pfizer Inc. (NYSE:PFE)

VeraBank N.A. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 4.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 35,048 shares of the biopharmaceutical company’s stock after selling 1,675 shares during the quarter. VeraBank N.A.’s holdings in Pfizer were worth $1,014,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. River Global Investors LLP raised its stake in Pfizer by 7.6% during the third quarter. River Global Investors LLP now owns 115,774 shares of the biopharmaceutical company’s stock worth $3,350,000 after acquiring an additional 8,211 shares in the last quarter. Tyler Stone Wealth Management grew its holdings in shares of Pfizer by 85.4% in the 3rd quarter. Tyler Stone Wealth Management now owns 31,156 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 14,353 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Pfizer by 12.8% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,067 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 462 shares in the last quarter. Baker Avenue Asset Management LP lifted its holdings in Pfizer by 9.1% during the 3rd quarter. Baker Avenue Asset Management LP now owns 32,860 shares of the biopharmaceutical company’s stock valued at $951,000 after purchasing an additional 2,738 shares during the last quarter. Finally, Mayflower Financial Advisors LLC boosted its position in Pfizer by 4.2% in the third quarter. Mayflower Financial Advisors LLC now owns 49,288 shares of the biopharmaceutical company’s stock valued at $1,426,000 after buying an additional 1,969 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.2 %

Shares of NYSE:PFE traded down $0.32 during trading on Friday, hitting $26.72. 55,951,315 shares of the company’s stock traded hands, compared to its average volume of 37,583,031. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $28.89 and a 200-day moving average price of $28.63. The company has a market cap of $151.42 billion, a price-to-earnings ratio of 36.11, a price-to-earnings-growth ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.29%. Pfizer’s dividend payout ratio is currently 227.03%.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.58.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.